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Renal calcium handling in familial hypocalciuric hypercalcemia. We
have determined calcium and sodium excretion rates in three members
of a kinship with familial hypocalciuric hypercalcemia (FHH) and in
four patients with primary hyperparathyroidism (PHP) under control
conditions and following the intravenous administration of chlorothja-
zide or furosemide. The characteristic hypocalciuria of FHH, evi-
denced by a significantly reduced urinary calcium/creatinine ratio
compared with that of PHP, is present under control conditions (0.08
vs. 0.26 mg calcium/mg creatinine, respectively, P < 0.05), and after
chlorothiazide (0.14 vs. 0.53, respectively, P < 0.01). However, after
furosemide infusion the calcium/creatinine ratio is no longer lower in
FHH than in PHP (1.12 vs. 1.14, respectively, P > 0.05). These data
suggest that, in FHH, tubular calcium reabsorption is enhanced in the
thick ascending limb of Henle's loop, the site of action of furosemide.
However, the data do not exclude the presence of an abnormality at a
more distal site in the nephron.
Elimination rénale du calcium dans l'hypercalcémie hypocalciurique
familiale. Nous avons déterminé les debits d'excrétion de calcium et de
sodium chez trois membres d'une famille avec une hypercalcemie
hypocalciurique familiale (FHH) et chez quatre malades avec un
hyperparathyroldisme primitif (PHP) dans des conditions contrôle et
aprés l'administration intra-veineuse de chlorothiazide de furosCmide.
L'hypocalciurie caracteristique de Ia FHH, mise en evidence par une
diminution significative du rapport calcium/créatinine urinaire par rap-
port a celui de PHP, est presente pendant les conditions contrôles (0.08
contre 0.26 mg calcium/mg crCatinine, respectivement, P < 0.05), et
apres chlorothiazide (0.14 contre 0.53, respectivement, P < 0.01).
Cependant, après perfusion de furosémide, le rapport calcium/créati-
nine ne demeure pas plus faible dans Ia FHH par rapport a PHP (1.12
contre 1.14, respectivement, P > 0.05). Ces données suggèrent que,
dans Ia FHH, Ia reabsorption tubulaire du calcium est augmentée dans
Ia branche ascendante large de l'anse de Henlé, le site d'action du
furosémide. Cependant ces données ne permettent pas d'exclure Ia
presence d'une anomalie située a un site plus distal du néphron.
Familial hypocalciuric hypercalcemia (FHH) [1—5] or familial
benign hypercalcemia 16, 7] is a hypercalcemic disorder which
is characteristically associated with a lower urinary calcium
excretion rate than that of typical primary hyperparathyroidism
(PHP). Other features of FHH include the frequent onset of
hypercalcemia in childhood, a clinical course relatively free of
complications and a lack of cure following subtotal parathyroid-
ectomy. The parathyroid glands are generally hyperplastic but
may appear normal [81. The glomerular filtration rate tends to
be higher in FHH than in PHP, and the ultrafilterability of the
plasma calcium does not differ from that of PHP [1], so that for
comparable degrees of hypercalcemia, glomerular filtration of
calcium is the same or greater in FHH than in PHP. By
contrast, urinary calcium excretion rate averages approximate-
ly one third of that of PHP, indicating enhanced tubular calcium
reabsorption. The relationship of this enhanced tubular calcium
reabsorption to the normal or increased parathyroid activity in
FHH is not understood; although a primary increase in renal
tubular calcium reabsorption might be expected to cause hyper-
calcemia, it would be expected also to lead to parathyroid gland
suppression. The plasma magnesium concentration tends to be
higher in FHH than in PHP, while fractional urinary magnesium
excretion is lower [1], suggesting increased renal tubular reab-
sorption of magnesium as well as calcium.
The mechanism of the hypocalciuria in FHH has not been
elucidated. Hypersensitivity to the enhancing effect of parathy-
roid hormone (PTH) tubular calcium reabsorption would cause
hypocalciuria. However, recent studies by Attic et al [9]
suggest that the hypocalciuria persists after total parathyroidec-
tomy in FHH.
To investigate the nephron site of enhanced tubular calcium
reabsorption in FHH, we examined the responses of patients
with FHH and PHP to the acute administration of chlorothia-
zide and furosemide. Chlorothiazide enhances tubular calcium
reabsorption (and inhibits sodium reabsorption) in the distal
convoluted tubule [101, while furosemide inhibits calcium [11,
12] as well as sodium [13] reabsorption in the thick ascending
limb of Henle's loop. We chose to compare FHH with PHP in
these studies since PHP appeared to be the most appropriate
control group, having comparable levels of hypercalcemia
without parathyroid suppression. The alternative possibility of
using calcium-infused normal subjects as controls was consid-
ered less satisfactory, since such subjects would have acute
parathyroid suppression.
Methods
Patients. Details of the three FHH and four PHP patients are
provided in Table 1. The subjects were all white females. The
three patients with FHH are members of a single kinship.
Patient 1, the propositus, was found to have hypercalcemia in
1977 at age 67. A neck exploration at that time revealed four
hyperplastic parathyroid glands, of which three were removed,
but she remained hypercalcemic. Patient 2. niece of patient 1,
was found to have hypercalcemia at age 32 in 1977. Patient 3,
whose grandfather is the brother of patient 1 and hypercalce-
mic, was found to have hypercalcemia in 1978 at age 22.
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Table 1. Subjects
Patient Age Weight
Serum 24-hr Urine
Ca P Mg PTH 1,25(OH)2D Ca Mg cAMPa Ccr
no. years kg mgldi mg/dI mg/di ng/mi pg/mi mg mg imo1es/g mi/mm
FHH
1 71 108 11.1 2.2 2.29 0.48" 60 156 76 4.67 55
2 36 51 11.1 2.3 2.33 0.09 60 141 91 5.00 119
3 26 50 12.4 2.3 2.23 0.12 47 116 103 5.01 82
Mean 44 70 11.5 2.3 2.28 56 138 90 4.89 85
SE ±14 ±19 ±0.4 ±0.03 ±0.03 ±12 ±12 ±8 ±0.11 ±19
PHP
4 52 53 12.1 2.9 2.60 0.23 57 227 86 4.95 63
5 22 60 10.5 2.6 1.68 0.12 76 271 90 4.57 91
6 67 57 11.1 2.5 2.53 0.22 60 375 — 5.88 73
7 57 46 11.5 2.7 2.20 l.01' — 363 74 5.76 75
Mean 50 54 11.3 2.7 2.25 64 309 83 5.29 76
± SE ±10 ±3 ±0.3 ±0.1" ±0.21 ±6 ±36" ±5 ±0.31 ±6
Abbreviations: FHH, familial hypocalciunc hypercalcemia; PHP, primary hyperparathyroidism; Ccr, creatinine clearance.
a Cyclic AMP was assayed by a RIA kit (Becton Dickinson) for which the normal range was 2.6 to 7.4 M/g creatinine except for patient 7 in
whom the assay used (Amersham) had a normal range of 2.2 to 4.3 M/g creatinine.
b P1'H was determined by radioimmunoassay using an antiserum which detects both C- and N-terminal portions of the molecule (normal range,
0.04 to 0.25 nglml, Dr. T. Murray, Toronto, Canada, except for patient I (Bio Science assay, normal range, 0.23 to 0.63 nglml as bovine PTH), and
patient 7c (Nichols Institute assay, C-terminal, normal <1.0 ng/ml).
d P <0.01, FHH vs. PHP.
Patients 2 and 3 have not had parathyroid surgery because they
have been recognized to have FHH. The diagnosis of FHH in
this family is based on the presence of hypercalcemia, apparent-
ly inherited as an autosomal dominant, in at least 12 of 21 family
members in four generations, and of neonatal onset in some
patients. In addition to patient 1, another family member has
had parathyroid surgery without cure. Affected family members
have hypercalcemia, hypocalciuria, a benign course, no renal
calculi, and no evidence of multiple endocrine neoplasia.
The diagnosis of PHP was based on the presence of chronic
hypercalcemia, elevated or nonsuppressed immunoreactive
PTH (iPTH) levels, and a lack of evidence for other causes of
hypercalcemia associated with typical clinical and biochemical
features of PHP. Patients 4 and 7 have had parathyroid explora-
tions. Patient 4 was found to have parathyroid hyperplasia. Two
glands were removed, but the patient remained hypercalcemic
postoperatively. In patient 7, only two normal glands were
identified in the neck and she has remained hypercalcemic
refusing further explorations. Patient 5, aged 22, has familial
multiple endocrine neoplasia type 1 and has not undergone
parathyroid surgery, Patient 6, aged 67, did not wish to have
surgical treatment. Results of serum PTH assays (using several
different radioimmunoassays) and serum 1 ,25(OH)2D assays
(using a chick intestine cytosol receptor assay) are shown in
Table I.
Study design. The responses to single intravenous doses of
chiorothiazide and furosemide were tested with a standard
protocol based on that of Breslau and Moses [14], allowing at
least I day of rest between tests. The patients were instructed to
follow a low calcium (approximately 400 mg/day) diet without
salt for a few days prior to tests and were permitted food and
fluid freely until 6 P.M. on the evening preceding the test day.
Patients fasted until the test was completed. Hourly urine
collections were made from 7 A.M. until 12 P.M. Water was
given orally; 200 ml at 7 A.M. followed by 50 ml hourly until 11
A.M. The test solution, 500 mg chlorothiazide in 50 ml 5%
dextrose, or 40 mg furosemide in 50 ml 5% dextrose, was
infused intravenously from 9 A.M. to 9:15 A.M. Venous blood
samples were collected at 9 A.M. and 11 A.M. for analysis for
total calcium, sodium, inorganic phosphorus, and creatinine;
urine samples were analyzed for calcium, sodium, inorganic
phosphorus, and creatinine. Blood and urine samples were also
analyzed for magnesium, except in patient 3. Most urine
samples were also analyzed for pH and bicarbonate concentra-
tion. All urinary ion excretions were factored by creatinine to
provide some standardization for body size and to reduce any
errors due to incomplete collections.
Results
Baseline data from the three patients with FHH and the four
with PHP are shown in Table 1. The two groups of patients did
not differ significantly with respect to mean plasma calcium
concentration (11.5 vs. 11.3 mg/dl, respectively, P > 0.05),
mean plasma magnesium concentration, (2.28 vs. 2.25 mg/dl, P
> 0.05), mean creatinine clearance (85 vs. 76 mI/mm, respec-
tively, P> 0.05) or mean urinary magnesium excretion (90 vs.
83 mg/24 hr, P > 0.05). Mean 24-hr urinary calcium excretion
was significantly lower in FHH than in PHP (138 vs. 309 mg, P
< 0.01). Mean serum inorganic phosphorus was significantly
lower in FHH than in PHP (2.3 vs. 2.7 mg/dl, P < 0.01). Serum
PTH levels were measured using different assays and cannot be
statistically compared but appear somewhat higher in PHP than
in FHH. Mean urinary cyclic AMP excretion was not signifi-
cantly lower in FHH than in PHP (4.89 vs. 5.29 zmoles/g
creatinine, P > 0.05). Individual values were within normal
range in FHH. Mean serum 1,25(OH)2D levels were not statisti-
cally different in the three FHH and three PHP patients in
whom they were measured (56 vs. 64 pg/mI, respectively, P>
0.05).
Table 2 summarizes the mean serum calcium, inorganic
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Table 2. Mean serum levels before and after chiorothiazide and
furosemide in FHH and PHP
Inorganic
Calcium
mg/dl
phosphorus
mg/dl
Magnesium
mg/dl
- Sodium
mEqiliter
Chlorothiazide
Before FHH 11.8 0.6 2.6 0.2 2.1 0.1' 139 0.3
PHP 11.3 0.2 2.6 0.1 2.3 0.2 142b 0.9
After FHH 12.2 0.5 2.7 0.1 2.2 0.1 137 0.3
PHP 11.3 0.4 2.6 0.1 2.3 0.1 140b 1.3
Furosemide
Before FHH 11.5 0.4 2.3 0.0 2.4 0.0' 138 1.4
PHP 11.4 0.3 2.7' 0.1 2.3 0.2 143 1.9
After FHH 11.6 0.4 2.3 0.1 2.3 0.2' 137 1.7
PHP 11.8 0.4 2.9° 0.1 2.4 0.1 142b 0.4
Abbreviations: FHH, familial hypocalciuric hypercalcemia; PHP,
primary hyperparathyroidism; N = 3 in FHH and 4 in PHP, except for
magnesium' where N = 2.
Comparison of FHH and PHP, P < 0.05b; P < 0.01'.
phosphorus, magnesium, and sodium levels before and after
chlorothiazide and furosemide in the two groups of patients. No
significant differences were observed between FHH and PHP in
regard to serum calcium, magnesium, or creatinine. Mean
serum inorganic phosphorus was significantly higher in PHP
than in FHH before and after furosemide but not before or after
chlorothiazide. Mean serum sodium was slightly but significant-
ly higher in PHP than in FHH before and after the administra-
tion of chlorothiazide and after the administration of
furosemide.
Table 3 shows the mean urinary calcium/creatinine (Ca/Cr,
mg/mg), sodiumlcreatinine (Na/Cr, mEq/mg), calcium/sodium
(Ca/Na, mg!mEq), magnesium/creatinine (Mg/Cr, mg/mg) and
inorganic phosphorus/creatinine (P/Cr, mg/mg) ratios for the
control periods preceding both diuretic infusions (hours I and 2)
and for the first two periods (hours 3 and 4) following the
infusion of chlorothiazide or furosemide. The last period (hour
5) was omitted, since the diuretic effects were waning in this
period (Fig. 1). Mean Ca/Cr was significantly lower in FHH
than PHP in the control periods (0.08 vs. 0.26, respectively, P <
0.05) and after chlorothiazide (0.14 vs. 0.53, respectively, P <
0.01). In both FHH and PHP, Ca/Cr increased approximately
twofold after chlorothiazide. The small increase in Ca/Cr fol-
lowing chlorothiazide occurred in all subjects and was statisti-
cally significant in PHP (0.27 0.07 vs. 0.53 0.07, P < 0.05)
but not in FHH (0.07 0.03 vs. 0.14 0.06, P > 0.05).
However, after furosemide mean Ca/Cr increased to approxi-
mately the same value in FHH and PHP (1.12 vs. 1.14,
respectively, P > 0.05). This represented an approximately 15-
fold increase over control in FHH, but only a fourfold increase
over control in PHP. Na/Cr was not significantly different
between FHH and PHP either during control periods, after
chiorothiazide (which increased Na/Cr five- to tenfold over
control) or after furosemide (which increased Na/Cr about 20-
fold over control). The Ca/Na ratio, which was significantly
lower in FHH than in PHP during the control periods (1.42 vs.
3.37, P <0.01) decreased approximately fivefold after chloro-
thiazide in both FHH and PHP, remaining significantly lower in
FHH (0.28 vs. 0.69 respectively, P < 0.025). This decrease in
Ca/Na ratio resulted from a marked increase in sodium excre-
tion associated with a small increase in calcium excretion in
Table 3. Calcium and sodium excretions during control periods and
after chlorothiazide and furosemide in FHH and PHP'
Periods
ControP'
1 and 2
Post-thiazide
3 and 4
Postfurosemide
3 and 4
Calcium/Creatinine,
mg/mg'
FHH 0.08 0.02
d
0.14 0.06
I
1.12 0.53
NS
PHP 0.26 0.05 0.53 0.07 1.14 0.08
Sodium/Creatinine,
mEq/mg
FHH 0.09 0.01
NS
0.49 0.18
NS
1.56 0.77
NS
PHP 0.08 0.02 0.78 0.03 1.69 0.16
Calcium/Sodium, mg/
mEq
FHH 1.42 0.28 0.28 0.02
'
0.78 0.07
NS
PHP 3.37 0.45 0.69 0.11 0.70 0.09
Magnesium/Creatinine,
mg/mg
FHH
PHP
0.07 0.01
NS
0.08 0.01
0.09 0.02
NS
0.10 0.02
0.37 0.18
(N =2)
NS
0.34 0.01
Inorganic phosphorus/
Creatinine, mg/mg
FHH 0.23 0.08
NS
0.38 0.07
NS
0.40 0.11
NS
PHP 0.41 0.13 0.67 0.16 0.40 0.09
'Values are mean SE.
b Control data were calculated using the average of all four control
collections for each subject (periods I and 2 before both infusions).
Post-thiazide and postfurosemide data were calculated using the aver-
age value for periods 3 and 4 for each subject.
'To convert to millimoles of electrolyte per millimole of creatinine,
multiply calcium ratio by 2.82, sodium ratio by 113, and magnesium
ratio by 4.63 and phosphate ratio by 3.53. To convert calcium/sodium
ratio to m, divide by 40. The significance of the difference between
FHH and PHP was: P < 0.05,d P < 0.025,' P < 0.01,1 NS = P> 0.05.
both groups. After furosemide, however, the Ca/Na ratios
became equal in FHH and PHP (0.78 vs. 0.70 respectively, P>
0.05).
Figure 1 shows the mean Ca/Cr and Na/Cr ratios for each
consecutive 1-hr period before (hours 1 and 2) and after (hours
3, 4, and 5) the infusions of chiorothiazide and furosemide.
Ca/Cr was consistently lower in FHH than PHP in the control
periods and after chlorothiazide, while after furosemide Ca/Cr
was not significantly different. Na/Cr was not significantly
different between FHH and PHP at any time, except during the
first hour after chlorothiazide (hour 3) when it was lower in
FHH.
Mean Mg/Cr and Pa/Cr ratios (Table 3) as well as bicarbonate!
creatinine ratios were not significantly different in FHH and
PHP before or after chlorothiazide or furosemide. Urinary
magnesium was determined in only two of the three FHH
patients before and after furosemide.
Discussion
In 1972 Foley et al [6] first described a family with benign
hypercalcemia inherited as an autosomal dominant, associated
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Fig. 1. Calcium/Creatinine and
Sodium/Creatinine ratios during control
periods (hours 1 and 2) and following
intravenous infusion of chiorothiazide [C] or
furosemide [F] (hours 3, 4, and 5) in FHH (•)
and PHP (0). To convert to millimoles of
electrolyte per millimole of creatinine,
multiply calcium ratio by 2.82 and sodium
ratio by 113. Values are mean SE. The
significance of the difference between FHH
and PHP was P < 0.05, **D < 0.025, ***D <
0.01.
Chiorothiazide Furosemide
1 2 3 4 5 1 2 3 4
Time, hours
1.5
5)C
1.0
E
0.5
a) 2.0
C
LuE 1.0
E6
0
with a low urinary calcium excretion rate and with normal
levels of iPTH. The administration of oral furosemide (40 mg
daily for I week) produced a sustained increase in urinary
sodium but only an initial increase in urinary calcium for the
first 24 hr. Since that time several further kindreds have been
described by Marx et al [1—4]. These patients also showed
higher mean glomerular filtration rates, higher mean serum
magnesium concentrations, lower urinary magnesium (as well
as calcium) excretion rates, and lower circulating iPTH and
urinary cyclic AMP levels than patients with typical PHP.
Our FHH patients belonged to a single kindred. Their mean
creatinine clearance was higher than that of the PHP patients,
but the difference was not significant. The FHH and PHP
patients had comparable degrees of hypercalcemia, and compa-
rable serum PTH and urinary cyclic AMP levels, as well as
similar mean I ,25(OH)2D levels. Serum phosphate was signifi-
cantly higher in PHP than FHH on the furosemide, but not the
chlorothiazide, study day. This difference in phosphate levels
has not been observed previously and its significance is uncer-
tain. The difference persisted after furosemide administration.
Our studies show that the characteristic hypocalciuria of
FHH (relative to PHP) persists after the administration of
chlorothiazide. The calcium/sodium ratios (mg/mEq) in FHH
and PHP, which were 1.42 and 3.37, respectively, in the control
phase, fell to 0.28 and 0.69, respectively, after chlorothiazide. A
fall in the urinary calcium/sodium ratio is the characteristic
response to chlorothiazide and is seen in the absence of
parathyroid hormone [15]. The fall in calcium/sodium ratio
results from a brisk natriuresis associated with little change (in
these studies a modest increase) in calcium excretion. The latter
presumably reflects the sum of two opposing effects. The
inhibition of sodium and water reabsorption in the distal convo-
luted tubule increases delivery to the more distal segments,
which would be expected to increase calcium excretion. At the
same time, however, thiazide directly stimulates calcium reab-
sorption in the distal convoluted tubule [10]. This latter effect
becomes evident as a fall in urinary calcium excretion after the
initial natriuresis has subsided. The similar responses in FHH
and PHP suggest that the component of distal calcium transport
that is responsive to chlorothiazide may be normal in FHH; that
is, the hypocalciuria in this disorder is probably not due to
augmentation of this component of distal calcium transport.
Following furosemide, however, the characteristic hypocal-
ciuria of FHH (relative to PHP) is abolished. Both sodium and
calcium excretion increase to comparable levels in FHH and
PHP, so that the calcium/sodium ratio becomes equal. Whereas
the natriuretic response is comparable, the rise in calcium
excretion is proportionately much greater in FHH than in PHP.
The main site of action of furosemide upon sodium and calcium
transport is the thick ascending limb of Henle's loop 112, 13], in
which reabsorption of sodium and calcium may be virtually
abolished by the drug [11]. The disappearance of the hypocal-
ciuria of FHH after furosemide suggests that the site of the
characteristic enhancement of calcium reabsorption in this
disease may be the thick ascending limb of Henle's loop, though
enhanced calcium absorption at more distal sites is not exclud-
ed. Furthermore, the observation that a relatively modest dose
of furosemide (sufficient to increase fractional sodium excretion
only to about 5% of filtered load) completely abolishes the
hyperabsorption of calcium in FHH suggests that the compo-
nent of calcium reabsorption that is enhanced in this disease
may be more susceptible to inhibition by furosemide than the
remaining component of calcium reabsorption in the thick
ascending limb. Evidence has been published recently suggest-
ing that there may be heterogeneity of calcium transport
processes along the thick ascending limb of Henle's loop [16].
Enhanced calcium reabsorption in the thick ascending limb of
Henle's loop in FHH could result from a selective increase in
the permeability of this segment to calcium, so that a given
driving force (the positive intraluminal potential difference)
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Would cause more calcium to be reabsorbed in FHH than in
PHP. Alternatively, since hypercalcemia is believed to inhibit
calcium reabsorption in Henle's loop 117, 18], the abnormality
in FHH may consist of a blunting of this inhibitory effect of
hypercalcemia upon calcium reabsorption. A similar blunting of
the normal inhibitory effect of hypercalcemia on the parathy-
roid glands is another characteristic of FHH, since PTH levels
are not suppressed by the hypercalcemia in this disorder.
Enhanced tubular reabsorption of magnesium, as well as
calcium, has been described in FHH [1], although in the present
study differences in magnesium excretion rates between PHP
and FHH were not significant. Hypercalcemia has been noted
to inhibit magnesium reabsorption in Henle's loop in one recent
study [19] but not in another [18]. The reduced urinary magne-
sium excretion that has been described in FHH [1] could
therefore be another manifestation of a blunted response to
hypercalcemia in this disorder.
The different calciuretic responses to chlorothiazide and
furosemide in FHH and PHP are not attributable to differences
in the urinary excretions of sodium, magnesium, phosphate, or
bicarbonate, none of which differed significantly before or after
the drugs in FHH and PHP. Nor were differences observed in
urine pH between FHH and PHP. The significantly lower
serum phosphate level in the FHH patients on the furosemide
(but not the chlorothiazide) study day seems unlikely to be
related to the different responses to this drug, since mean
control Ca/Cr and Na/Cr ratios were similar on the furosemide
and chiorothazide study days. The small but significant differ-
ence in mean plasma sodium concentration between FHH and
PHP (Table 2) also seems unlikely to have influenced the
diuretic responses, since urinary sodium excretions were simi-
lar in the two groups.
In conclusion, therefore, we have shown that the characteris-
tic hypocalciuria of FHH persists after chlorothiazide but is
abolished by furosemide. This observation suggests that the
hypocalciuria in FHH may result from hyperabsorption of
calcium in the thick ascending limb of Henle's loop, the site at
which furosemide exerts its effect. However, a more distal site
for calcium hyperabsorption in FHH is not excluded. The
relationship between the tubular defect and the hypercalcemia
in FHH remains unclear. Since the parathyroid glands are not
suppressed in FHH, it is possible that both the thick ascending
limb of Henle's loop and the cells of the parathyroid gland share
an insensitivity to the normal physiological effects of hypercal-
cemia in this disorder.
